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Background: Recombinant human granulocyte colony stimulating factor (rhG-CSF) is a first line therapy for neutropenia. 
However, it is less affordable for most patients in developing and poor countries. Therefore, biosimilar products are 
developed to suppress the cost of treatment, namely with rhG-CSF. This study aimed to explore the establishment of an 
affordable rhG-CSF that has similar potential to  induce  neutrophils  recovery as the positive control.
Materials and Methods: The rhG-CSF was expressed as inclusion body in Escherichia coli NiCo21(DE3). The inclusion body 
was then solubilized, refolded, purified and characterized prior to be used in the bioactivity assay. Cyclophosphamide-
induced male Sprague Dawley rats were used as animal model and administered with rhG-CSF. Blood sample was collected 
at several points of time, before and after rhG-CSF treatments. Complete blood count and peripheral blood smear were 
conducted to investigate the activity of the rhG-CSF on each blood cells type, particularly neutrophil. 
Results: Specific activity on neutrophil proliferation was shown after treatments with our rhG-CSF and positive control. 
Positive control dose 40 mg/kg BW was statistically similar with that of the rhG-CSF dose 80 and 120 mg/kg BW. However, 
in neutropenic condition, recovery of neutrophil counts could not be achieved within 4 days of treatments. Thus, a longer 
treatment is needed to observe the activity of the rhG-CSF as an antineutropenia agent. 
Conclusion: The rhG-CSF has been proven having specific activity on neutrophil proliferation. However, improvement in the 
rhG-CSF preparation is still needed and longer administration of the rhG-CSF has to be applied in the future study.
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Introduction
Granulocyte colony stimulating factor (G-CSF) or colony 
stimulating factor 3 (CSF-3) is a glycoprotein-cytokine 
with around 20 kDa molecular weight that plays role in 
hematopoesis control, particularly in neutrophils maturation.1 
Lacking of G-CSF generates reduction of progenitor cells in 
bone marrow and spleen.2 Chemotherapy administration is 
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known as the main cause the progenitor cells suppression.3-5 
Neutropenia or condition with neutrophil less than 1500 
cells/µL is generally found in patients with cancer who 
received chemotherapy regimen.3 Lower neutrophils counts 
in peripheral blood attenuates immune response, thus 
patients with neutropenia are vulnerable to infection. In 
patients with cancer, infection leads to severe complication 
and increases death risk.3 Therefore, synthetic G-CSF is 
then suggested for patients receiving such chemotherapy 
treatments. It induces proliferation and differentiation of 
neutrophils to regain normal counts of neutrophils in the 
peripheral blood (1500-8000 cells/µL).6,7 
 The synthetic G-CSF or filgrastim or Neupogen which 
was developed as a recombinant protein and produced in 
Escherichia coli was approved for clinical used in 1991.8,9 
It has been used as the first line therapy for chemotherapy-
induced neutropenia and proven to be well tolerated by the 
patients.10 
 Following the patent expiration of Neupogen as 
the recombinant human G-CSF (rhG-CSF) originator, 
development of rhG-CSF biosimilar has become 
interesting for researchers and pharmaceutical industries. 
The biosimilar products are potential to reduce cost for 
development and manufacturing, thus they are potentially 
marketed with almost 50% lower price than the originator 
is.11,12 A list of rhG-CSF biosimilars has been approved 
by drug regulator such as European Medicine Agency 
(EMA), namely Tevagrastim (2008); Ratiograstim (2008); 
Biograstim (2008); Filgrastim Hexal (2009);  Zarzio (2009); 
Nivestim (2010); Grastofil (2013); and Accofil (2014).13
 Our group has developed and characterized the 
synthetic soluble thioredoxin fused-rhG-CSF (Trx-rhG-
CSF) in E. coli expression system. However, purification 
of rhG-CSF from Trx is high cost and low-yielding.14-17 
Therefore, in this study, rhG-CSF was expressed as 
insoluble protein without Trx-fusion and found abundantly 
in inclusion body agregates which are caused by misfolded 
protein. The inclusion body was then solubilized and 
purified to obtain active rhG-CSF.18 The active rhG-CSF 
was evaluated and compared with a commercial rhG-CSF 
which has been marketed and clinically used in Indonesia. 
 The activity of our rhG-CSF as antineutropenia agent 
was investigated using cyclophosphamide induced animal 
model. Cyclophosphamide is an alkylating agent used as 
antineoplastic and immunosuppresants. It binds to a DNA 
strand resulting inhibition of cancer cells proliferation.19,20 
However, by reason of non-selective action, it is 
potential to cause a number of adverse effects, such as 
myelosuppresion, haemorrhagic cystitis, gastrointestinal 
toxicity, infection, and also includes neutropenia.21,22 
Therefore, cyclophosphamide was frequently used in 
preclinical study to develop neutropenic animal model.23-25 
In the recent study, the induced animal model was treated 
with the rhG-CSF in various doses and compared with 
positive control that  had been  tested  in  a  pre-clinial 
study.26   Complete blood cells analysis was performed to 
monitor the effect of rhG-CSF on each types of blood cell, 
particularly on neutrophils. This study aimed to explore 
whether we could established an affordable rhG-CSF that 
has similar potential to  induce  neutrophils  recovery as 
positive control in treating neutropenia, particularly after 
chemoterapy regimen. 
Materials and methods
Expression, Purification, and Characterization of rhG-
CSF
The rhG-CSF was expressed as inclusion body from an 
expression vector patented in Patent No. P00201708906 by 
IPTG induction 0.1 mM (Thermo Scientific, Massachusetts, 
USA) in Luria Bertani medium which was incubated at 
37°C, 150 rpm, overnight.27 From 100 mL cells culture, 
cells pellet was obtained by centrifugating at 6,000 rpm 
for 6’ and then resuspended in phosphate buffer saline 
enriched with 1 mM phenylmethylsulfonyl fluoride 
(PMSF). The cells were disrupted by sonification for 5’ on 
ice and washed in buffer pH 7.9 containing 20 mM Tris-
Cl, 5 mM ethylenediaminetetraacetic acid (EDTA), 0.5% 
Triton-x. Afterwards, the remaining pellet that was known 
as inclusion body was solubilized and refolded.18 Refolded 
protein was purified using Amicon® Centrifugal filter 10 
and 30 molecular weight cut-off (MWCO) (Merckmillipore, 
Massachusetts, USA). Profiles of solubilized and refolded 
protein were analyzed with Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
characterized with western blot using monoclonal anti-rhG-
CSF antibody. All other chemical reagents were purchased 
from Merck (Darmstad, Germany) and Sigma (Santa Cruz, 
USA). 
Preparation of Recombinant Human Granulocyte Colony 
Stimulating Factor Dosage Form
The purified rhG-CSF was lyophilized in phosphate 
buffer saline using a freeze dryer (Alpha 1-4 LDPlus, 
Christ, Osterode am Harz, Germany). It was immediately 
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reconstituted in sterile aquabidest (Ikapharmindo Putramas, 
Jakarta, Indonesia) before administered in animal model. 
The positive control, Leukokine (Novell Pharmaceutical 
Laboratories, Bogor, Indonesia) was reconstituted in 5% 
dextrose (Widatra Bhakti, Jakarta, Indonesia) following 
the manual instruction. Each reconstituted rhG-CSF with 
different doses, positive control (before reconstituted), and 
not lyophilized rhG-CSF were analyzed for absorbance and 
fluorescence spectrum using Varioskan (Thermo Scientific).
Administration of rhG-CSF to Neutropenic Male Rats 
Sprague Dawley
The following procedure was approved by Animal Care and 
Use Committee of Institut Pertanian Bogor – ACUC No. 84-
2017. Healthy male Sprague Dawley rats aged 2-3  months 
with body weight 200-300 g (Biofarmaka, Institut Pertanian 
Bogor, Indonesia) were selected and grouped into six 
groups (six rats per group). Each groups acquired different 
treatments as follow: Group 1 as normal control which was 
not received either cyclophosphamide (Endoxan) induction 
or rhG-CSF treatment; Group 2 as negative control received 
5% dextrose, subcutaneous (s.c);  Group 3 as positive 
control (Leukokine 40µg/kg BB, s.c); Group 4; 5; and 6 
administered with the rhG-CSF 40; 80; 120 µg/kg BW, s.c, 
respectively. Positive control dose was calculated with dose 
conversion from human to rat.28 
 The experiment design, specifically in time of 
induction, treatment, and blood sampling was referred 
to previous study.23 Rats in Group 2-6 were induced with 
cyclophosphamide 100 mg/kg BW, intra peritoneally (i.p) 
at 24 h after baseline blood sampling (Day -1). The rhG-
CSF treatments were started at 24 h after cyclophosphamide 
induction and continued for 4 days, once per day. Volume 
administration of cyclophosphamide, dextrose, and rhG-
CSF was 2.5 mL/ kg BW. Blood sampling (approximately 
0.5 mL) was carried out from lateral tail vein on Day 1 and 
Day 4, 6 h after treatments on the same day. The rats were 
sacrificed on the Day 5 by ketamine (Kepro) and xylazin 
(Interchemie, Netherlands) injection (75 mg/kg BW, 8 mg/
kg BW, intramuscular (i.m), 2.5mg/kg BW). Subsequently, 
approximately 2-3 mL of blood was collected from left 
cardiac vein. 
Blood and Organs Analyzes
Blood samples were analyzed by using hematology analyzer 
(VetScan HM5, Abaxis, California, USA) for complete 
blood count and peripheral blood smear with Giemsa 
staining (Merck). Comparison of each groups at the same 
sampling time were analyzed by using One Way ANOVA 
SPSS 16.0 (IBM Corporation, New York, USA), followed 
by PosHoc Multiple Comparison – Ducan Method with 
significance level 0.5. 
Results
Expression, Purification, and Characterization of rhG-
CSF
A significant band was found at size approximately 17 kDa 
in supernatant after solubilization. As an addition data, 
remaining pellet after solubilization was also analyzed 
on SDS-PAGE and showed more abundance of rhG-CSF 
but containing endogenous contaminant proteins from 
expression host E.coli NiCo21(DE3) (Figure 1A). In order 
to obtain rhG-CSF in an active form, the solubilized rhG-
CSF was refolded and purified. The rhG-CSF which had 
been prepared in native form was then analyzed with non-
reducing PAGE as depicted in Figure 1B. The native form 
of rhG-CSF was found at approximately 14-15 kDa in size. 
This non-reducing PAGE was used to confirm that refolded 
process had been completed. It is shown in Figure 1B lane 
2 and 4 in which migration of positive control and refolded 
protein was similar. As expected, migration of solubilized 
protein (Figure 1B, lane 3) was slighly faster compared 
than migration of positive control and refolded protein. 
However, smear migration was found in the refolded rhG-
CSF which was not as clean as positive control (Figure 1B). 
Result of western blotting is shown in Figure 1C. Both of 
our rhG-CSF and positive control positively bound to the 
monoclonal anti-rhG-CSF antibody.  
 As supplementary data, graphs of absorbance and 
fluorescence spectrum were prepared to access physical 
similarity of our rhG-CSF and positive control. Those 
proteins, except not-lyophilized rhG-CSF, have similar 
absorbance spectrum with optimum wavelenght at 
approximately 276 nm (Figure 2A). Moreover, the profiles 
of fluorescence spectrum of positive control and rhG-
CSF dose 40; 80; and 120 mg/kg BB were also similar, 
but spectrum of rhG-CSF dose 40 mg/kg BB had higher 
intensity (Figure 2B).
Bioactivity Assay of rhG-CSF to Blood Cells Profile of 
Male Sprague Dawley Rats
Numbers  of  each  type  of  blood  cell,  i.e.,  leukocytes, 
platelets, and erythrocytes are represented in the following 
graphs (Figure 3). Neutrophils, lymphocytes, and monocytes 
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Figure 1. Protein profiles of rhG-CSF. A: SDS PAGE of isolation and solubilization of inclusion bodies, 1) protein marker, 
2) supernatant after washing, 3) sitoplasmic protein, 4) supernatant after solubilization, 5) pellet excess of solubilization. 
B: Non reducing PAGE rhG-CSF, 1) protein marker, 2) Leukokine as positive control, 3) solubilized rhG-CSF or before 
refolding, 4) refolded rhG-CSF. C: Western blot of rhG-CSF against monoclonal anti rhG-CSF antibody, 1) protein marker, 
2) concentrated and refolded rhG-CSF, 3) positive control.
were obtained as percentage in the leukocyte. In Figure 
3, they are represented as cell counts by calculating the 
percentage towards leukocytes total count. Basophils and 
eosinophils were found extremely low in rat bloods, thus 
not detected by the hematology analyzer. 
 Significant differences were found in leukocytes and 
neutrophils count on Day 1 in groups treated with positive 
control; rhG-CSF dose 40 and 80 μg/kg BW compared to 
normal and negative control group. However, on Day 4 and 
5, no differences of leukocytes and neutrophils count were 
found among groups. Except leukocytes and neutrophils 
count, rhG-CSF did not affect other types of blood cell 
(Figure 3). 
 Density of blood cells (erythrocytes) were manually 
observed and found similar among normal, rhG-CSF dose 
80μg/kg BW, and positive control on Day 1. In addition, 
neutrophils were easily found in rhG-CSF dose 80 μg/kg 
BW and positive control group. On Day 5, all groups showed 
reduction in blood cells (erythrocytes) density (Figure 4).
Discussion
The recent study was initiated by cyclophosphamide 
administration to gain neutropenic animal model. Likewise 
other chemotherapy agents, cyclophosphamide induces 
bone marrow suppression or myelosuppresion causing 
depletion of blood cells (erythrocytes, leucocytes and 
platelets) counts. It inhibits proliferation of hematopoetic 
progenitor cells (HPC), so the degeneration of new blood 
cells is neglected. Extensive cyclophosphamide exposure 
does not only impact the HPC, but also perturbs renewal 
of hematopoietic stem cells (HSC) that causes more severe 
effects such as bone marrow failure or even death.29,30 
 All types of blood cells (erythrocytes, leukocytes, 
and platelets) gradually deteriorated by cyclophosphamide 
induction (Figure 1).  On the last day, all of the blood cells 
parameters were below normal range for male rats aged 
2-4 months31, whereas the blood cells counts in normal 
group were relatively steady. However, erythrocytes in 
normal group were slightly declined that probably due to 
blood sampling. From the same data, it is known that only 
neutrophils were affected by rhG-CSF administration. 
The graph of neutrophil count corresponded with that of 
leukocytes’ one, even though lymphocytes are the most 
dominant cells in the leukocytes. It indubitably proves that 
the rhG-CSF specifically acts on neutrophils regeneration, 
not on other blood cells. This led by G-CSF receptors 
(G-CSFR) are expressed in neutrophils and their precursors 
including HSC and HPC.32 
 In our experiment, the administration of rhG-CSF and 
positive control significantly increased the neutrophils count 
on Day 2 only. However, at that time point, neutropenic 
condition was not achieved because the neutrophils count 
of negative control group was not significantly lower than 
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Figure 2. Absorbance and 
flourescence spectrum of rhG-
CSF and positive control. 
A: asbsorbance spectrum; B: 
fluorescence spectrum of rh-
GCSF and positive control.
that of normal group. It means that either the rhG-CSF or 
positive control did increase the neutrophils count, but not 
in neutropenic condition. 
 Similar effect was found in the rhG-CSF dose 80; 120 
mg/kg; and the positive control 40 mg/kg. This indicates 
that in order to obtain similar activity in same dose with 
the positive control, preparation of the obtained rhG-CSF 
needs to be improved, including dispensing, purification, 
refolding, and lyophilization.
 The refolded rhG-CSF was purified from other 
contaminants protein, which is dominantly found at 
approximately 33 kDa, by centrifugal filter with 30 kDa cut 
off and then concentrated by centrifugal filter with 10 kDa 
cut off (Figure 1B). In order to obtain clean purified rhG-
CSF as the positive control, an advanced purification such 
as size exclusion or ion-exchange chromatrography need to 
be applied. 
  In addition, similarity of biological activity of positive 
control; rh-GCSF dose 80 mg/kg; and 120 mg/kg was 
supported by fluorescence spectrum. The fluorescence 
spectrum  of  those  groups  had  the  same  profile  and 
intensity.   
 Since neutropenia condition did not meet yet on Day 
2, the adminitrastion of rhG-CSF and positive control led 
over-proliferation of  neutrophils counts which reached 
>5000, and considered as neutrophilia (normal neutrophil 
counts on rat 2-4 months = 220-1570).15 Moreover, Welte 
and Lim performed similar experiment by administrating 
G-CSF on healthy animal model, also resulting neutrophilia 
in 4 h and 24 h after injection, respectively.26,33 
 Cyclophosphamide started to suppress neutrophil 
counts on day 3. Therefore, on the day 3 rats underwent 
neutropenia (<220) and became severe on day 4 (<50).24  
However, in the experiment set, neutrophil counts were 
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Figure 3. Complete blood count of blood sample at Day -1 (baseline 
or before cyclophosphamide induction), Day 1 (6 h after treatments 
on Day 1), Day 4(6 h after treatments on Day 4), and Day 5 (30 h 
after treatments on Day 4).
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Figure 4. Microscopic visualization of peripheral blood smear, with 100x magnification. 
Red bar: 20 mm.
not boosted by the rhG-CSF and positive control in 
the neutropenic condition. In keeping with Welte and 
colleagues’ report, a significant effect of rhG-CSF was 
observed after 8 days of treatment in cyclophosphamide-
induced monkey.33 The neutrophils that were counted until 
34 days remained in normal range after receiving rhG-CSF 
for 20 days. Therefore, in regards to our experiment, it is 
assumed  that  the  activity  of  the  rhG-CSF  in  neutropenia 
condition needs be observed with longer regimen which is 
more than 4 days. 
 17
Bioassay of rhG-CSF for Neutropenia Treatment Pratiwi RD, et al.
Conclusion
The rhG-CSF that had been produced in our lab showed 
similar potency in increasing neutropils count in health 
animals compared with the positive control, but needed 2-3 
time higher dose. The effects of both the obtained rhG-CSF 
and positive control to enhance neutrophils production in 
neutropenic animal models could not be evaluated in the 
current study due to short rhG-CSF administration and 
observation period. Hence, it is suggested that in the further 
study, the administration of rhG-CSF is requested in longer 
period of time. In addition, downstream processes of our 
rhG-CSF have to be improved and more characterzations 
are required.
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